MET receptor tyrosine kinase inhibitor-containing pharmaceutical composition and application thereof

The invention discloses a pharmaceutical composition containing an MET receptor tyrosine kinase inhibitor and application. Specifically, a pharmaceutical combination comprising (i) an MET receptor tyrosine kinase inhibitor 6-(1-methyl-1H-pyrazol-4-yl)-1-((6-(1-methyl-1H-pyrazol-4-yl) imidazole [1, 2-a] pyridine-3-yl) sulfonyl)-1H-pyrazoline [4, 3-b] pyridine or a pharmaceutically acceptable salt thereof, and an EGFR mutant inhibitor or a pharmaceutically acceptable salt thereof. A method and use for treating or preventing cancer using said combination. The combination has beneficial therapeutic properties such as synergistic interaction, strong anti-proliferative activity in vitro or in vivo and/or strong anti-tumor response in vitro or in vivo, making it particularly suitable for the treatment of cancer. 一种含MET受体酪氨酸激酶抑制剂的药物组合物及应用。具体地，一种药物组合，其包含(i)MET受体酪氨酸激酶抑制剂6-(1-甲基-1H-吡唑-4-基)-1-((6-(1-甲基-1H-吡唑-4-基)咪唑[1，2-a]吡啶-3基)磺酰基)-1H-吡唑啉[4，3-b]吡啶或其药学上可接受的盐，以及EGFR突变体抑制剂或其药学上可接受的盐。一种使用所述组合来治疗或预防癌症的方法和用途。所述组合具有有益的治疗特性，如协同相